FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga

Saved in:
Bibliographic Details
Published in:Nucleic acid therapeutics Vol. 27; no. 1; pp. 1 - 3
Main Authors: Aartsma-Rus, Annemieke, Krieg, Arthur M.
Format: Journal Article
Language:English
Published: Los Angeles, CA Mary Ann Liebert, Inc 01.02.2017
SAGE Publications
Subjects:
Adolescent
Child
Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Approval
Dystrophin - genetics
Exons
Humans
Issues in Development
Morpholinos - therapeutic use
Muscular Dystrophy, Duchenne - drug therapy
Muscular Dystrophy, Duchenne - economics
Oligonucleotides - therapeutic use
Time Factors
Treatment Outcome
United States
United States Food and Drug Administration
Walk Test
Young Adult
splicing modulation
therapy
regulatory
oligonucleotide
ISSN:2159-3337, 2159-3345, 2159-3345
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2159-3337
2159-3345
2159-3345
DOI:10.1089/nat.2016.0657